MediciNova, Inc. (MNOV) EPS Estimated At $-0.14

Investors sentiment decreased to 1.47 in Q1 2019. Its down 0.22, from 1.69 in 2018Q4. It turned negative, as 3 investors sold MediciNova, Inc. shares while 12 reduced holdings. 4 funds opened positions while 18 raised stakes. 9.04 million shares or 0.93% less from 9.13 million shares in 2018Q4 were reported.
Credit Suisse Ag invested in 11,134 shares or 0% of the stock. Northern Trust invested in 0% or 506,148 shares. State Of Wisconsin Inv Board has invested 0% in MediciNova, Inc. (NASDAQ:MNOV). California-based Charles Schwab Inv Mngmt has invested 0% in MediciNova, Inc. (NASDAQ:MNOV). Bnp Paribas Arbitrage accumulated 8,284 shares. New York State Common Retirement Fund holds 40,867 shares. 3,274 are held by Ameritas Partners Incorporated. 51,528 were accumulated by Rhumbline Advisers. California Public Employees Retirement System owns 40,800 shares for 0% of their portfolio. Moreover, Vanguard Grp Incorporated has 0% invested in MediciNova, Inc. (NASDAQ:MNOV). Alliancebernstein L P holds 0% in MediciNova, Inc. (NASDAQ:MNOV) or 19,400 shares. Alps Advsrs holds 0.01% or 101,861 shares in its portfolio. California State Teachers Retirement Systems owns 63,761 shares for 0% of their portfolio. Barclays Plc owns 0% invested in MediciNova, Inc. (NASDAQ:MNOV) for 12,093 shares. Manufacturers Life Insur The invested in 27,671 shares or 0% of the stock.

Analysts expect MediciNova, Inc. (NASDAQ:MNOV) to report $-0.14 EPS on July, 22.They anticipate $0.06 EPS change or 75.00 % from last quarter’s $-0.08 EPS. After having $-0.11 EPS previously, MediciNova, Inc.’s analysts see 27.27 % EPS growth. The stock increased 14.51% or $1.32 during the last trading session, reaching $10.42. About 431,189 shares traded or 205.63% up from the average. MediciNova, Inc. (NASDAQ:MNOV) has risen 25.58% since July 14, 2018 and is uptrending. It has outperformed by 21.15% the S&P500.

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company has market cap of $448.70 million. The company??s product candidate includes MN-166 , an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. It currently has negative earnings. The Company’s product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a ??2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers.

More notable recent MediciNova, Inc. (NASDAQ:MNOV) news were published by: which released: “MediciNova Announces MN-001 Research Collaboration with The Jikei University School of Medicine in Tokyo, Japan – GlobeNewswire” on March 05, 2019, also with their article: “MediciNova Announces the Publication of Results of the Animal Model Study of MN‑166 (ibudilast) in Glioblastoma in Scientific Reports – GlobeNewswire” published on February 28, 2019, published: “The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs – Yahoo Finance” on May 04, 2019. More interesting news about MediciNova, Inc. (NASDAQ:MNOV) were released by: and their article: “MediciNova Announces Clinical Data from Subgroup Analyses of Completed Clinical Trial of MN-166 (ibudilast) in ALS – GlobeNewswire” published on July 09, 2018 as well as‘s news article titled: “MediciNova up 2% premarket on potential approval path for MN-166 in ALS – Seeking Alpha” with publication date: September 26, 2018.

MediciNova, Inc. (NASDAQ:MNOV) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.